$HOTH
Hoth Therapeutics, Inc. Stock $hoth

$hoth Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023066246 Filed on August 11, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.050M	$1.010M
YoY Change	21.47%	325.13%
% of Gross Profit
Research & Development	$1.246M	$641.0K
YoY Change	-14.14%	-34.0%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$2.093M	$1.709M
YoY Change	-22.03%	-25.7%
Operating Profit	-$2.093M	-$1.709M
YoY Change	-22.03%	-25.7%
Interest Expense	$10.00K	-$164.4K
YoY Change	-75.47%	-56.48%
% of Operating Profit
Other Income/Expense, Net	$6.397K	-$164.4K
YoY Change	-84.08%	-56.51%
Pretax Income	-$2.090M	-$1.873M
YoY Change	-20.96%	-30.05%
Income Tax
% Of Pretax Income
Net Earnings	-$2.087M	-$1.873M
YoY Change	-21.09%	-30.05%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.60	-$0.57
Diluted Earnings Per Share	-$0.75	-$0.57
COMMON SHARES
Basic Shares Outstanding	3.302M shares	3.302M shares
Diluted Shares Outstanding	3.484M shares	3.302M shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.85M	$11.57M
YoY Change	27.92%	-0.45%
Cash & Equivalents	$11.83M	$11.54M
Short-Term Investments	$24.57K	$24.57K
Other Short-Term Assets	$200.0K	$314.9K
YoY Change	4.48%	64.7%
Inventory
Prepaid Expenses	$200.3K	$314.9K
Receivables
Other Receivables
Total Short-Term Assets	$12.05M	$11.88M
YoY Change	26.78%	0.18%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$30.00K	$33.00K
YoY Change	-92.26%	-91.48%
Other Assets
YoY Change
Total Long-Term Assets	$33.00K	$33.00K
YoY Change	-91.48%	-91.48%
TOTAL ASSETS
Total Short-Term Assets	$12.05M	$11.88M
Total Long-Term Assets	$33.00K	$33.00K
Total Assets	$12.09M	$11.92M
YoY Change	22.15%	-2.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$707.2K	$520.7K
YoY Change	-24.03%	-23.37%
Accrued Expenses	$871.7K	$1.162M
YoY Change	1560.29%	2258.26%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.579M	$1.716M
YoY Change	56.57%	127.7%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$250.0K
YoY Change	-100.0%	-9.09%
Total Long-Term Liabilities	$0.00	$250.0K
YoY Change	-100.0%	-9.09%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.579M	$1.716M
Total Long-Term Liabilities	$0.00	$250.0K
Total Liabilities	$1.579M	$1.966M
YoY Change	23.02%	91.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$51.24M	-$49.16M
YoY Change	23.12%	26.12%
Common Stock	$435.00	$330.00
YoY Change	237.21%	-89.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.51M	$9.951M
YoY Change
Total Liabilities & Shareholders Equity	$12.09M	$11.92M
YoY Change	22.15%	-2.72%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$2.087M	-$1.873M
YoY Change	-21.09%	-30.05%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$1.640M	-$1.450M
YoY Change	-31.34%	-34.78%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.410M	0.000
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-1.640M	-1.450M
Cash From Investing Activities	0.000	0.000
Cash From Financing Activities	2.410M	0.000
Net Change In Cash	770.0K	-1.450M
YoY Change	-132.37%	-129.31%
FREE CASH FLOW
Cash From Operating Activities	-$1.640M	-$1.450M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$1.640M	-$1.450M
YoY Change	-31.63%	-33.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.40
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.16
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1100990	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2894732	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38803
	dei	Entity Registrant Name EntityRegistrantName	Hoth Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-1553794
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1 Rockefeller Plaza
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1039
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10020
	dei	City Area Code CityAreaCode	(646)
	dei	Local Phone Number LocalPhoneNumber	756-2997
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
	dei	Trading Symbol TradingSymbol	HOTH
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3302113	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11544802	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6428611	usd
CY2023Q2	us-gaap	Marketable Securities MarketableSecurities	24567	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	209320	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	314881	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	88450	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	11884250	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6726381	usd
CY2023Q2	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	33000	usd
CY2022Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	33000	usd
CY2023Q2	us-gaap	Assets Assets	11917250	usd
CY2022Q4	us-gaap	Assets Assets	6759381	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	520658	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	694989	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1161680	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	667742	usd
CY2023Q2	hoth	Accrued License Fee Current Portion AccruedLicenseFeeCurrentPortion	33750	usd
CY2022Q4	hoth	Accrued License Fee Current Portion AccruedLicenseFeeCurrentPortion	25000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1716088	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1387731	usd
CY2023Q2	hoth	Accrued License Fee Non Current Portion AccruedLicenseFeeNonCurrentPortion	250000	usd
CY2022Q4	hoth	Accrued License Fee Non Current Portion AccruedLicenseFeeNonCurrentPortion	250000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	1966088	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1637731	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3302113	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3302113	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1302113	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1302113	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	330	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	130	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	59130198	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	50198630	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-49155654	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-45099116	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-23712	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	22006	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	9951162	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5121650	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11917250	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6759381	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	640959	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	971182	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1531804	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1919561	usd
CY2023Q2	hoth	Research And Development License Acquired ResearchAndDevelopmentLicenseAcquired	11243	usd
CY2022Q2	hoth	Research And Development License Acquired ResearchAndDevelopmentLicenseAcquired	36453	usd
	hoth	Research And Development License Acquired ResearchAndDevelopmentLicenseAcquired	59276	usd
	hoth	Research And Development License Acquired ResearchAndDevelopmentLicenseAcquired	77725	usd
CY2023Q2	hoth	Compensation And Related Expensesincluding Stockbased Compensation CompensationAndRelatedExpensesincludingStockbasedCompensation	518476	usd
CY2022Q2	hoth	Compensation And Related Expensesincluding Stockbased Compensation CompensationAndRelatedExpensesincludingStockbasedCompensation	515090	usd
	hoth	Compensation And Related Expensesincluding Stockbased Compensation CompensationAndRelatedExpensesincludingStockbasedCompensation	814040	usd
	hoth	Compensation And Related Expensesincluding Stockbased Compensation CompensationAndRelatedExpensesincludingStockbasedCompensation	1472859	usd
CY2023Q2	us-gaap	Professional Fees ProfessionalFees	483883	usd
CY2022Q2	us-gaap	Professional Fees ProfessionalFees	523595	usd
	us-gaap	Professional Fees ProfessionalFees	1100258	usd
	us-gaap	Professional Fees ProfessionalFees	1010296	usd
CY2023Q2	hoth	Rent Expenses RentExpenses	7897	usd
CY2022Q2	hoth	Rent Expenses RentExpenses	15591	usd
	hoth	Rent Expenses RentExpenses	23017	usd
	hoth	Rent Expenses RentExpenses	29487	usd
CY2023Q2	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	46171	usd
CY2022Q2	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	237636	usd
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	373051	usd
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	450313	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	1708629	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	2299547	usd
	us-gaap	Operating Expenses OperatingExpenses	3901446	usd
	us-gaap	Operating Expenses OperatingExpenses	4960241	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1708629	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2299547	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3901446	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4960241	usd
CY2023Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-165950	usd
CY2022Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-216127	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-184753	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-194179	usd
CY2022Q2	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-158636	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-158635	usd
CY2022Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-22600	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-22600	usd
CY2023Q2	us-gaap	Dividend Income Operating DividendIncomeOperating	1548	usd
CY2022Q2	us-gaap	Dividend Income Operating DividendIncomeOperating	19579	usd
	us-gaap	Dividend Income Operating DividendIncomeOperating	29661	usd
	us-gaap	Dividend Income Operating DividendIncomeOperating	45132	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-262	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	41423	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-164402	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-378046	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-155092	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-288859	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1873031	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2677593	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4056538	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5249100	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-51088	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	14230	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-45718	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	10500	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1924119	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2663363	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4102256	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5238600	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.4
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.77
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3302113	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1241398	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2894732	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1100990	shares
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	11865533	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	9748	usd
CY2023Q2	hoth	Cumulative Translation Adjustments CumulativeTranslationAdjustments	-51088	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1873031	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	9951162	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	7884493	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	15538	usd
CY2022Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1014896	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5985103	usd
CY2022Q2	hoth	Cumulative Translation Adjustments CumulativeTranslationAdjustments	14230	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2677593	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	11221771	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5121650	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1860	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	20378	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	8909530	usd
	hoth	Cumulative Translation Adjustments CumulativeTranslationAdjustments	-45718	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4056538	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	9951162	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9882292	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	592976	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1014896	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5985103	usd
	hoth	Cumulative Translation Adjustments CumulativeTranslationAdjustments	10500	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5249100	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	11221771	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4056538	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5249100	usd
	hoth	Research And Developmentlicenses Acquired Expensed ResearchAndDevelopmentlicensesAcquiredExpensed	8750	usd
	hoth	Research And Developmentlicenses Acquired Expensed ResearchAndDevelopmentlicensesAcquiredExpensed	61453	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-22600	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	20378	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	592976	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-194179	usd
	us-gaap	Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments	-184753	usd
	us-gaap	Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments	-158635	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	227391	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	101090	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	330933	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-38762	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3739115	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4359109	usd
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	76453	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1235696	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1159243	usd
	hoth	Proceed From Issuance Common Stock Common Stock Warrants And Prefunded Warrants Net Of O ProceedFromIssuanceCommonStockCommonStockWarrantsAndPrefundedWarrantsNetOfO	8909530	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5985103	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1860	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8911390	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5985103	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-56084	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-5972	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	5172275	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2785237	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6428611	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8538270	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11544802	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11317535	usd
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	140000	shares
CY2022Q4	hoth	Common Stock Shares Purchase CommonStockSharesPurchase	1860000	shares
CY2022Q4	hoth	Warrants Purchase To Shares WarrantsPurchaseToShares	2500000	shares
CY2022Q4	hoth	Common Stock At Purchase Price CommonStockAtPurchasePrice	5
CY2022Q4	hoth	Aggregate Gross Proceeds AggregateGrossProceeds	10000000	usd
CY2022Q4	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	5
	hoth	Warrant Exercisable Term Description WarrantExercisableTermDescription	The December Wainwright Warrants are exercisable for a period of five and one-half years from the issuance date at an exercise price of $6.25 per share, subject to adjustment, and may, under certain circumstances, be exercised on a cashless basis.
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reclassifications</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. These reclassifications had no impact on net income (loss), stockholder’s equity or cash flows as previously reported. The reclassification included separating dividend income from gain on marketable securities within the condensed consolidated statements of operations and comprehensive loss.</p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s condensed consolidated financial statements relate to stock-based compensation and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations may be affected.</p>
	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	11544802	usd
CY2022	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	6428611	usd
	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	250000	usd
CY2023Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	10726329	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	5542838	usd
	hoth	Australian Bank Accounts AustralianBankAccounts	318473	usd
CY2022	hoth	Australian Bank Accounts AustralianBankAccounts	385771	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentrations of credit risk and off-balance sheet risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company has significant cash balances at financial institutions which, throughout the period, regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</p>
	us-gaap	Interest Income Federal Funds Sold InterestIncomeFederalFundsSold	250000	usd
CY2023Q2	us-gaap	Accounts Payable Other Current And Noncurrent AccountsPayableOtherCurrentAndNoncurrent	260000	usd
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3110875	shares
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	507567	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3110875	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	507567	shares
	hoth	Schedule Of Research And Development Expenses For Licenses Acquired ScheduleOfResearchAndDevelopmentExpensesForLicensesAcquired	The following summarizes the Company’s research and development expenses for licenses acquired (including stock-based compensation) during three and six months ended June 30, 2023 and 2022:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended<br/> June 30,</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">For the Six Months Ended<br/> June 30,</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">The George Washington University</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,618</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,953</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">51,776</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40,225</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: middle; "> <td style="text-align: left">North Carolina State University</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="text-align: left">Virginia Commonwealth University</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: middle; "> <td style="padding-bottom: 1.5pt">University of Cincinnati</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">625</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,250</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,243</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">36,453</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">59,276</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">77,725</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q2	hoth	Research And Development Expenses ResearchAndDevelopmentExpenses	11243	usd
CY2022Q2	hoth	Research And Development Expenses ResearchAndDevelopmentExpenses	36453	usd
	hoth	Research And Development Expenses ResearchAndDevelopmentExpenses	59276	usd
	hoth	Research And Development Expenses ResearchAndDevelopmentExpenses	77725	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	30000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	30000	usd
CY2023Q2	us-gaap	Other Expenses OtherExpenses	10618	usd
	us-gaap	Other Expenses OtherExpenses	51776	usd
CY2023Q2	us-gaap	Marketable Securities MarketableSecurities	24567	usd
CY2023Q2	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	33000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	209320	usd
CY2022Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	33000	usd
CY2023Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	33000	usd
CY2023Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	33000	usd
CY2022Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	33000	usd
CY2023Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	33000	usd
CY2022Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	410000	usd
CY2022Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-22600	usd
CY2022Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	387400	usd
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	410000	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-22600	usd
CY2022Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	387400	usd
CY2022	us-gaap	Change In Unrealized Gain Loss On Hedged Item In Fair Value Hedge1 ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1	27000	usd
	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	33000	usd
CY2022	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	33000	usd
CY2022Q4	us-gaap	Securities Purchased Under Agreements To Resell Setoff Rights Description SecuritiesPurchasedUnderAgreementsToResellSetoffRightsDescription	(i) 140,000 shares of common stock, (ii) December Pre-Funded Warrants to purchase up to 1,860,000 shares of common stock and (iii) December Common Stock Warrants to purchase up to 2,500,000 shares of common stock at a purchase price of $5.00 per share and accompanying warrant (less $0.001 for each December Pre-Funded Warrant) in a private placement for aggregate gross proceeds of approximately $10 million, exclusive of placement agent commission and fees and other offering expenses, and approximately $8.9 million in net proceeds. The closing of the offering occurred on January 3, 2023.
CY2021Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	66878	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	3384	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.16
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	3384	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.16
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	6000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P1Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	104651	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	49.8
	hoth	Sharebased Compensation Arrangement By Sharebased Payment Award Option Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	104651	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	49.8
	hoth	Weighted Average Remaining Contractual Lifein Years Outstanding Ending Balance WeightedAverageRemainingContractualLifeinYearsOutstandingEndingBalance	P7Y9M18D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	104651	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	49.8
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y9M18D
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested	0	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9748	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15538	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20378	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	592976	usd
CY2022Q4	us-gaap	Common Unit Issued CommonUnitIssued	140000	shares
CY2022Q4	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	2500000	shares
CY2022Q4	hoth	Purchase Price Per Share PurchasePricePerShare	5
CY2022Q4	hoth	Accompanying Warrant Per Share AccompanyingWarrantPerShare	0.001
CY2022Q4	hoth	Gross Proceeds GrossProceeds	10000000	usd
CY2022Q4	hoth	Common Stock Warrant Term Description CommonStockWarrantTermDescription	Each December Common Stock Warrant is exercisable for a period of five and one-half years from the issuance date at an exercise price of $5.00 per share, subject to adjustment, and may, under certain circumstances, be exercised on a cashless basis.
CY2023Q1	us-gaap	Share Price SharePrice	6.56
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2023Q1	us-gaap	Long Term Debt Term LongTermDebtTerm	P30Y
CY2023Q1	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	5
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.3507	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0394	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	15000000	usd
CY2023Q2	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	591090	usd
	hoth	Schedule Of Warrant Activity ScheduleOfWarrantActivity	A summary of warrant activity for the six months ended June 30, 2023 is as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; padding-bottom: 1.5pt">Outstanding as of December 31, 2022</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">402,840</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">49.73</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">—</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">1.4</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,460,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.94</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">—</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,860,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.001</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Outstanding as of June 30, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,002,840</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">11.04</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.58</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Warrants exercisable as of June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">3,002,840</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11.04</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">4.58</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>
	hoth	Leases Office Spaces LeasesOfficeSpaces	2500	usd
CY2023Q2	us-gaap	Payments For Rent PaymentsForRent	7897	usd
CY2022Q2	us-gaap	Payments For Rent PaymentsForRent	15591	usd
	us-gaap	Payments For Rent PaymentsForRent	23017	usd
	us-gaap	Payments For Rent PaymentsForRent	29487	usd
CY2023Q2	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss		usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss		usd
CY2023Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1		usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1		usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1241398	shares
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1		usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment		usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	hoth	Proceed From Issuance Common Stock Common Stock Warrants And Prefunded Warrants Net Of O ProceedFromIssuanceCommonStockCommonStockWarrantsAndPrefundedWarrantsNetOfO		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1		usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		usd
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001711786

Files In Submission

Name	View Source	Status
0001213900-23-066246-index-headers.html	Edgar Link	pending
0001213900-23-066246-index.html	Edgar Link	pending
0001213900-23-066246.txt	Edgar Link	pending
0001213900-23-066246-xbrl.zip	Edgar Link	pending
f10q0623ex31-1_hoththerap.htm	Edgar Link	pending
f10q0623ex31-2_hoththerap.htm	Edgar Link	pending
f10q0623ex32-1_hoththerap.htm	Edgar Link	pending
f10q0623ex32-2_hoththerap.htm	Edgar Link	pending
f10q0623_hoththerap.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hoth-20230630.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
hoth-20230630_cal.xml	Edgar Link	unprocessable
hoth-20230630_def.xml	Edgar Link	unprocessable
hoth-20230630_lab.xml	Edgar Link	unprocessable
hoth-20230630_pre.xml	Edgar Link	unprocessable
f10q0623_hoththerap_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HOTH
Hoth Therapeutics, Inc. Stock $hoth

2023 Q3 Form 10-Q Financial Statement

#000121390023066246 Filed on August 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HOTH Hoth Therapeutics, Inc. Stock $hoth

2023 Q3 Form 10-Q Financial Statement

#000121390023066246 Filed on August 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HOTH
Hoth Therapeutics, Inc. Stock $hoth